NCT07458347

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-04-21Est. Completion: 2027-06

Enrollment target: 145 participants

Locations

Cedars-Sinai Medical Center, Los Angeles, California, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston, Massachusetts, United States
Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States

Contact

Kestrel Therapeutics, Inc.clinicaltrials@kestreltherapeutics.com 617-612-6810

Other microbiome trials you might be interested in

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationPhase 1Recruiting

KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNon-Small Cell Lung CarcinomaNonsmall Cell Lung CancerColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsNeoplasms, Colorectal

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with ad…

Boston, United StatesEst. completion Sep 30, 2026

View Trial →

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.